A comparison of the efficacy of donepezil in parkinson's disease with dementia and dementia with lewy bodies

International Journal of Geriatric Psychiatry

Volumn 20, Issue 10, 2005, Pages 938-944

  Thomas, Alan J ^a   Burn, David J ^a   Rowan, Elise N ^a   Littlewood, Elizabeth ^a   Newby, Jane ^a   Cousins, David ^a   Pakrasi, Sanjeet ^a   Richardson, Jonathan ^a   Sanders, Jonathan ^a   McKeith, Ian G ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cholinesterase inhibitors; Demetia; DLB; Donepezil; Parkinson's disease

Indexed keywords

ANTIDEPRESSANT AGENT; DONEPEZIL; HYPNOTIC AGENT; LEVODOPA; NEUROLEPTIC AGENT;

AGED; AGITATION; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; COGNITION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DYSPNEA; FALLING; FEMALE; HALLUCINATION; HEADACHE; HEALTH BEHAVIOR; HEPATITIS; HUMAN; HYPERSALIVATION; INSOMNIA; LACRIMAL GLAND DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MINI MENTAL STATE EXAMINATION; MUSCLE CRAMP; NAUSEA; NEUROPSYCHIATRY; OPEN STUDY; PARKINSON DISEASE; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREMOR; URINE INCONTINENCE; VOMITING;

AGE FACTORS; AGED; CHOLINESTERASE INHIBITORS; DEMENTIA; FEMALE; HUMANS; INDANS; LEWY BODY DISEASE; MALE; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PIPERIDINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 30344485150     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.1381     Document Type: Article

References (38)

1. Aarsland D, Laake K, Larsen JP, Janvin C. 2002. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 72: 708-712.
2. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. 1999. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 14: 866-874.
3. Aarsland D, Mosimann UP, McKeith IG. 2004. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 17: 164-171.
4. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC.
5. Ballard C, O'Brien J, Morris CM, et al. 2001. The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease. Int J Geriatr Psychiatry 16: 499-503.
6. Ballard CG, Aarsland D, McKeith I, et al. 2002. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 59: 1714-1720.
7. Ballard CG, Lowery K, Powell I, O'Brien J, James I. 2000. Impact of behavioral and psychological symptoms of dementia on caregivers. Int Psychogeriatr 12: 93-105.
8. Bergman J, Lerner V. 2002. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 25: 107-110.
9. Bucks RS, Ashworth DL, Wilcock GK, Siegfried K. 1996. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing 25: 113-120.
10. Bullock R, Cameron A. 2002. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 18: 258-264.
11. Burn DJ, Rowan EN, Minnett T, et al. 2003. Extrapyramidal features in Parkinson's Disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov Disord 8: 884-889.
12. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. 1994. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-2314.
13. Emre M. 2003. Dementia associated with Parkinson's disease. Lancet Neurol 2: 229-237.
14. Emre M, Aarsland D, Albanese A, et al. 2004. Rivastigmine for Dementia Associated with Parksinson's Disease. N Engl J Med 351: 2509-2518.
15. Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. 2002. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 23: 41-43.
16. Fahn S, Elton RL, Members UP. 1987. Unified Parkinson's Disease Rating Scale. In Recent Dev Parkinson's Disease, Vol. 2, Fahn SER, Marsden CD, Goldstein M, Calne DB (eds). MacMillan Healthcare Information: Florham Park, NJ; 153-163.
17. Folstein MF, Folstein SE, McHugh PR. 1975. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
18. Gibb WRG, Lees AJ. 1988. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51: 745-752.
19. Grace J, Daniel S, Stevens T, et al. 2001. Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 13: 199-205.
20. Korczyn AD, Shabati H, Benbunan B, et al. 2001. The effect of treatment with rivastigmine (Exelon) on cognitive functions of patients with dementia and Parkinson's disease. Parkinsonism Relat Disord 7: S61.
21. Lanctot KL, Herrmann N. 2000. Donepezil for behavioural disorders associated with Lewy bodies: a case series. Int J Geriatr Psychiatry 15: 338-345.
22. McKeith IG, Burn DJ. 2000. Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. In Neurol Clin: Dementia, Vol. 18, DeKosky ST (ed.). Philadelphia: W.B. Saunders Philadelphia, PA; 865-883.
23. McKeith I, Del Ser T, Spano P, et al. 2000a. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356: 2031-2036.
24. McKeith IG, Galasko D, Kosaka K, et al. 1996. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47: 1113-1124.
25. McKeith IG, Grace JB, Walker Z, et al. 2000b. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 15: 387-392.
26. McKeith IG, Wesnes K, Perry E, Ferrara R. 2004. Hallucinations predict attentional improvements with Rivastigmine in Dementia with Lewy Bodies. Dement Geriatr Cogn Disord 18: 94-100.
27. Minett TSC, Thomas AJ, Wilkinson LM, et al. 2003. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry 18: 988-993.
28. Perry EK, Haroutunian V, Davis KL, et al. 1994. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 5: 747-749.
29. Perry EK, Irving D, Kerwin JM, et al. 1993. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 7: 69-79.
30. Perry EK, Morris CM, Court JA, et al. 1995. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience 64: 385-395.
31. Reading PJ, Luce AK, McKeith IG. 2001. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 16: 1171-1174.
32. Salmon DP, Thal LJ, Butters N, Heindel WC. 1990. Longitudinal evaluation of dementia of the Alzheimer type: a comparison of three standardized mental status examinations. Neurology 40: 1225-1230.
33. Samuel W, Caligiuri M, Galasko D, et al. 2000. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 15: 794-802.
34. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B. 1997. Validity and Reliability of the Alzheimer's Disease Cooperative Society - Clinical Global Impression of Change. Alzheimer Dis Assoc Disord 11: 22-32.
35. Shea C, MacKnight C, Rockwood K. 1998. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 10: 229-238.
36. Van Laar T, de Vries JJ, Nakhosteen A, Leenders KL. 2001. Rivastigmine as anti-psychotic treatment in patients with Parkinson's disease. Parkinsonism Relat Disord 7: S73.
37. Walker MP, Ayre GA, Cummings JL, et al. 2000. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry 177: 252-256.
38. Werber EA, Rabey JM. 2001. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm 108(11): 1319-1325.